The company is trying to develop a one-time treatment for forms of heart disease that afflict more than 1 million people in ...

According to the latest study from BCC Research, "Cell and Gene Therapy Tools, and Reagents: Global Markets," is estimated to ...

Solid Biosciences (SLDB) stock was launched by Truist with a Buy rating based on positive catalysts and attractive valuation.

Bryan Johnson, who’s spending hundreds of millions of dollars on treatments designed to extend his life, is many things to ...

Researchers have successfully repaired damaged mouse hearts using a protein from zebrafish. They discovered that the protein Hmga1 plays a key role in heart regeneration in zebrafish. In mice, this ...

The data suggests that Hmga1, a key protein for regenerating heart cells, could be a target for gene therapies that prevent cardiac failure.

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease Proceeds of financing will ...

New Gene Therapy Reverses Heart Failure in Large Animal Model Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart ...